Understanding ROS1-positive Lung Cancer with Dr. Alice Shaw скачать в хорошем качестве

Understanding ROS1-positive Lung Cancer with Dr. Alice Shaw

No topic is off-limits. No question is too uncomfortable. No experience is too raw to share. Welcome to Living With Lung Cancer: Ask Me Anything, the survivor-led podcast that strips away clinical jargon to reveal what living with lung cancer really looks like. In this episode, Dr. Alice Shaw from Dana-Farber Cancer Institute joins host Annabelle Gurwitch to discuss ROS1-positive lung cancer, a rare but treatable form of the disease affecting only 1-2% of lung cancer patients. What You'll Learn: • What "oncogene-driven" lung cancer means and why it's actually good news • Why comprehensive biomarker testing is essential for all NSCLC patients • The difference between tissue and liquid biopsy testing • How ROS1 targeted therapies have evolved over the past 15 years • Next-generation treatments: more potent, selective, with fewer side effects • How new drugs penetrate the brain to treat and prevent metastases • Clinical trial participation while maintaining your local care team • Why specialized care matters for rare mutations • Resources and advocacy groups for ROS1 patients Dr. Shaw explains how next-generation ROS1 inhibitors represent a quantum leap forward in treatment, offering better efficacy with cleaner safety profiles. She discusses the rapid pace of drug development and why clinical trials offer access to the most advanced treatments available. Whether you're newly diagnosed with ROS1-positive lung cancer, supporting a loved one, or interested in the latest research, this conversation provides hope through scientific advancement—not empty platitudes, but real progress that saves lives. Timestamps: 00:00 Introduction to Living With Lung Cancer: Ask Me Anything 00:54 What is oncogene-driven lung cancer? 04:37 The critical importance of biomarker testing 07:42 Tissue vs. liquid biopsy: when to use each 11:55 Understanding ROS1-positive lung cancer 14:51 Evolution of ROS1 treatments over 15 years 17:35 Next-generation inhibitors and reduced side effects 19:44 Brain penetration: treating and preventing metastases 22:13 Clinical trials timeline and participation 24:38 How to advocate for clinical trial access 27:01 Working with both local and specialized care teams 30:48 The critical importance of targeted therapies 33:15 Hope through scientific advancement About Our Guest: Dr. Alice Shaw is Director of the Center for Thoracic Cancers at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She is an internationally recognized expert in targeted therapies for lung cancer, particularly for patients with ALK and ROS1 rearrangements. Her groundbreaking research has been instrumental in developing next-generation targeted therapies that have transformed outcomes for patients with rare oncogene-driven lung cancers. Learn more: https://www.dana-farber.org/find-a-do... About Our Host: Annabelle Gurwitch is a New York Times bestselling author, LCFA Speakers Bureau member, and lung cancer survivor. Diagnosed with EGFR-mutated lung cancer five years ago, she brings her signature wit and unflinching honesty to conversations about life with lung cancer, cutting through platitudes to reveal the real truth of survival. Learn more: https://lcfamerica.org/speaker-profil... Resources Mentioned: • ROS Wonders - Patient community for ROS1-positive patients • Dana-Farber Cancer Institute Thoracic Oncology: https://www.dana-farber.org/cancer-ca... • LCFA Second Opinion Resources: https://lcfamerica.org/resources/seco... • Financial assistance programs and patient support Subscribe to Living With Lung Cancer: Ask Me Anything: Apple Podcasts | Spotify | Amazon Music | iHeart Join LCFA's Community: Website: https://lcfamerica.org/ Facebook:   / lungcancerfoundation   Twitter:   / lcfamerica   Instagram:   / lcfamerica   YouTube:    / lcfamerica   Supported by: Elevate Lung Cancer Care, an initiative backed by Nuvalent, which aims to empower patients with clearer information and better treatment conversations. Learn more: https://elevatelungcancercare.com/ Have a topic or question for a future episode? Share it here: https://lcfamerica.org/living-with-lu... More Episodes: • Financial Toxicity in Lung Cancer Care: https://lcfamerica.org/story/financia... • Side Effects & Lung Cancer: The Hidden Realities: https://lcfamerica.org/story/side-eff... This is Living With Lung Cancer: Ask Me Anything—raw conversations, real survivors, no filters. LungCancer #ROS1 #TargetedTherapy #PatientAdvocacy #LCFA #CancerResearch #Oncology #LungCancerAwareness #BiomarkerTesting #PrecisionMedicine #RareCancer #LungCancerCommunity #CancerSurvivor #DrAliceShaw #DanaFarber #AnnabelleGurwitch #LivingWithLungCancer #AskMeAnything